Sotera Health (NASDAQ:SHC) Releases FY24 Earnings Guidance

Sotera Health (NASDAQ:SHC) issued an update on its FY24 earnings guidance on Thursday morning. The company provided EPS guidance of $0.67 to $0.75 for the period, compared to the consensus EPS estimate of $0.71. The company issued revenue guidance of +4 to +6% yr/yr or $1.091 billion to $1.112 billion, compared to the consensus revenue estimate of $1.10 billion.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the company. Royal Bank of Canada reiterated an outperform rating and issued a $20.00 price target on shares of Sotera Health in a report on Monday, March 4th. Jefferies Financial Group raised Sotera Health from a hold rating to a buy rating and boosted their price target for the company from $15.00 to $15.50 in a research report on Monday, March 25th. Barclays dropped their price target on Sotera Health from $19.00 to $14.00 and set an overweight rating for the company in a research note on Wednesday, April 10th. TheStreet raised Sotera Health from a d rating to a c- rating in a research note on Tuesday, February 27th. Finally, Citigroup raised shares of Sotera Health from a neutral rating to a buy rating and dropped their target price for the stock from $18.00 to $16.00 in a research report on Wednesday, April 3rd. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of Moderate Buy and a consensus price target of $17.70.

Sotera Health Stock Performance

Shares of Sotera Health stock traded up $0.11 on Friday, reaching $11.02. 1,039,496 shares of the company were exchanged, compared to its average volume of 1,036,531. Sotera Health has a 1-year low of $10.71 and a 1-year high of $19.40. The firm has a market cap of $3.12 billion, a price-to-earnings ratio of 58.00 and a beta of 2.08. The company has a debt-to-equity ratio of 5.18, a quick ratio of 2.21 and a current ratio of 3.20. The company’s 50-day moving average is $12.45 and its two-hundred day moving average is $14.01.

Sotera Health (NASDAQ:SHC) last posted its earnings results on Tuesday, February 27th. The company reported $0.26 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.26. Sotera Health had a net margin of 5.09% and a return on equity of 48.47%. The firm had revenue of $310.24 million during the quarter, compared to analyst estimates of $302.17 million. During the same period in the previous year, the business posted $0.23 EPS. Sotera Health’s revenue was up 23.3% on a year-over-year basis. As a group, research analysts expect that Sotera Health will post 0.63 earnings per share for the current fiscal year.

Insider Activity

In other Sotera Health news, insider Michael P. Rutz sold 83,109 shares of the company’s stock in a transaction on Monday, March 4th. The stock was sold at an average price of $14.31, for a total value of $1,189,289.79. Following the transaction, the insider now owns 544,409 shares of the company’s stock, valued at $7,790,492.79. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other news, Director Pincus & Co. Warburg sold 16,594,363 shares of Sotera Health stock in a transaction that occurred on Monday, March 4th. The shares were sold at an average price of $14.31, for a total value of $237,465,334.53. Following the transaction, the director now directly owns 88,822,952 shares of the company’s stock, valued at $1,271,056,443.12. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Michael P. Rutz sold 83,109 shares of the company’s stock in a transaction that occurred on Monday, March 4th. The shares were sold at an average price of $14.31, for a total transaction of $1,189,289.79. Following the completion of the sale, the insider now owns 544,409 shares of the company’s stock, valued at approximately $7,790,492.79. The disclosure for this sale can be found here. Insiders own 55.12% of the company’s stock.

About Sotera Health

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.